NCT04713319View on ClinicalTrials.gov

Novel Energy Metabolic Signaling Molecule With Therapeutic Potential

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

October 4, 2019

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Healthy Participants
Interventions
DRUG

Panavital

In the morning and evening a dose of Placebo or D-glyceric acid (DGA) calcium salt dehydrate (Panavital) dissolved into 1.8 dl of water.

OTHER

Placebo

In the morning and evening a dose of Placebo or D-glyceric acid (DGA) calcium salt dehydrate (Panavital) dissolved into 1.8 dl of water.

Trial Locations (1)

FI-40014

Faculty of Sports and Health Sciences, University of Jyväskylä, Jyväskylä

All Listed Sponsors
collaborator

University of Jyvaskyla

OTHER

lead

Petteri Hirvonen

INDUSTRY

NCT04713319 - Novel Energy Metabolic Signaling Molecule With Therapeutic Potential | Biotech Hunter | Biotech Hunter